Forecast Insight: HIV – Increasing Dominance of Fixed Dose Combinations Raises Bar for Single Agents by Datamonitor Now Available at ReportsandReports

In 2009, HIV antiretroviral sales across the seven major markets totaled $11.8 billion, growing at a CAGR of 10.8% between 2005 and 2009.

Dallas, TX, August 13, 2010 --( ReportsandReports Announce it Will Carry Forecast Insight: HIV – Increasing dominance of fixed dose combinations raises bar for single agents Market Research Report in its Store.

Browse the complete Report on:

In 2009, HIV antiretroviral sales across the seven major markets totaled $11.8 billion, growing at a CAGR of 10.8% between 2005 and 2009. While new cross-class fixed dose combinations will ensure market growth until 2015, Datamonitor expects major patent expiries and rising pressure to reduce healthcare costs to trigger a decline in HIV sales in the second half of the forecast period until 2019.

- Analysis of the current and future market dynamics for HIV antiretrovirals across the US, 5EU and Japan, supported by insights of key opinion leaders.
- Detailed sales forecasts for the major antiretroviral classes, molecules and brands in each of the seven major markets.
- Thorough assessment of key marketed antiretroviral brands and late stage pipeline products.
- Snapshot of HIV drug sales in the Rest of World by region.

In 2009 Atripla replaced Truvada as top-selling antiretroviral in the seven major markets, illustrating the increasing popularity of one-pill-once-a-day treatment regimens. This trend is set to intensify following the launch of Tibotec/J&J/Gilead’s Truvada/rilpivirine and Gilead’s Quad pill from 2012 onwards.

Despite predicting continuously rising sales for Prezista until 2013, Datamonitor expects protease inhibitors overall to see the highest sales loss on a class level over the forecast period due to an empty pipeline and the dominance of cross-class fixed dose combinations.

Datamonitor anticipates the increasing pressure to reduce healthcare costs to lead to more cost-control measurements across the seven major markets, resulting in enhanced possibilities for generics to penetrate the HIV drug market. This, in combination with key patent expiries, will result in a decline of HIV antiretroviral sales from 2016 onwards.

Browse all Healthcare at

Browse all Datamonitor at

Browse Latest Reports at:

Related Reports:
Forecast Insight: HIV - Cross-class fixed dose combinations drive continued growth

Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries

Forecast Insight: Antithrombotics - Market growth dependent on new agents

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Akshata Patil